CONSIDER AMYLOID PLAQUE BIOMARKER TESTING AS THE NEXT STEP FOR YOUR PATIENTS
Amyvid is used to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline3
- Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products3
Consider Amyvid for patients you’re evaluating who:
- Are displaying early signs of cognitive impairment where AD is suspected3,4
- Have already started the diagnostic process (labs, cognitive assessment, EEG, MRI, etc.)4-6
- Are concerned about memory slips
- Want to know what may be the cause of their cognitive impairment
- Are open to treatment options and want an informed diagnosis for next steps
Use Amyvid to help support a clinical AD diagnosis. Amyvid can help select appropriate patients with AD who are indicated for amyloid beta–directed therapy.3
EEG = electroencephalogram; MRI=magnetic resonance imaging.
SELECT IMPORTANT SAFETY INFORMATION
Risk for Image Misinterpretation and Other Errors
- Errors may occur in the estimation of brain amyloid beta neuritic plaque density during Amyvid image interpretation.
- The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to an inaccurate assessment. Extensive brain atrophy as well as motion artifacts that distort the image may limit the ability to distinguish gray and white matter on an Amyvid scan.
Perform image interpretation independently of the patient’s clinical information. For cases where there is uncertainty as to the location of cortical signal, use co-registered anatomical imaging to improve localization of signal.
Choose Amyvid to aid in the clinical diagnosis of AD and the selection of patients who are indicated for amyloid beta–directed therapy3
See how Amyvid can fit into your patient’s diagnostic plan.
Amyvid is used to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline3
- Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products3
*Hypothetical patient.
- 70-year-old art teacher—widowed since 2012
- Enjoys painting and being with her 3 grandchildren
- Arrives 30 minutes late for her visit, seems anxious
- Describes her morning as “chaos” trying to get her grandchildren to school
- Reports more difficulty with memory for the past 2 years and asks, “This is just normal for my age, right?”
- Repeats the same story about her morning twice
- MMSE 26/30
Clinical Assessment: MCI
Complete history and physical are normal, including neurological exam—reveals no focal deficits
Routine lab tests normal, as well as TSH, B12, and folate6
Structural MRI is read as "age-appropriate atrophy"6
Diagnosis is MCI: Follow-up scheduled in 3 months–family member is requested to attend6
An Amyvid PET scan is ordered to differentiate diagnosis and decide, along with Charlotte, on appropriate management3
Amyvid PET Scan Imaging Report3
POSITIVE SCAN†
- Establishes the presence of moderate-to-frequent amyloid-beta neuritic plaques
- Neuropathological examination has shown that moderate-to-frequent amyloid-beta neuritic plaques are present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition
The objective of Amyvid image interpretation is to provide an estimate of the brain amyloid-beta neuritic plaque density. Image interpretation is performed independently of a patient's clinical features and relies upon the recognition of unique image features.
The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to errors.3
*Hypothetical patient.
†Amyvid PET scans are interpreted independently of the patient’s clinical information.3
SELECT IMPORTANT SAFETY INFORMATION
Risk for Image Misinterpretation and Other Errors
- Errors may occur in the estimation of brain amyloid beta neuritic plaque density during Amyvid image interpretation.
- The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to an inaccurate assessment. Extensive brain atrophy as well as motion artifacts that distort the image may limit the ability to distinguish gray and white matter on an Amyvid scan.
Perform image interpretation independently of the patient’s clinical information. For cases where there is uncertainty as to the location of cortical signal, use co-registered anatomical imaging to improve localization of signal.
PROCEDURE: BRAIN AMYLOID PET/CT SCAN
HISTORY: Cognitive impairment
COMPARISON: None
RADIOPHARMACEUTICAL: 10mCi Amyvid (florbetapir F 18)
TECHNIQUE: PET/CT imaging was performed 30-50 minutes following the intravenous administration of 10mCi Amyvid (florbetapir F 18). Images were obtained from the level of the vertex to the base of the skull. Axial, sagittal, and coronal PET reconstructions were acquired.
Corresponding CT images were reviewed in axial, coronal, and sagittal planes. CT scan was a limited noncontrast study and used for anatomical correlation and attenuation correction.
COMMENT: There is diffusely increased tracer uptake throughout the cortical cerebral gray matter. Most intense uptake is seen in the prefrontal, lateral temporal, and parietal areas, with these areas showing clear loss of the normal gray-white contrast. The cerebellum has no evidence of abnormal uptake.
Tracer distribution is otherwise unremarkable.
CT (NONDIAGNOSTIC, PERTINENT FINDINGS ONLY): There is mild cerebral volume loss without mass effect or midline shift.
IMPRESSION: Positive scan, indicating moderate to frequent beta-amyloid neuritic plaques
NOTE: Amyvid is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline
- Selection of patients who are indicated for amyloid beta–directed therapy as described in the prescribing information of the therapeutic products
MCI=mild cognitive impairment; MMSE=Mini-Mental State Examination; MRI=magnetic resonance imaging; PET=positron emission tomography; TSH=thyroid-stimulating hormone.
Amyvid is used to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline3
- Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products3
*Hypothetical patient.
71-year-old accountant with cognitive concerns
- Accompanied to doctor’s office by his wife of 40 years
- Wife describes his progressive change over the past 3 years
- Gradually lost ability to work with numbers; his wife now manages their finances
- Used to enjoy lively dinner conversation; now he is less talkative
- His memory is worse, but sometimes recalls nearly everything
- Paul is frustrated by these changes
- MOCA 24/30 with errors in recall, calculation, attention, and visuospatial skills
Clinical Assessment: Progressive MCI
Medical history is remarkable for hypertension, type 2 diabetes, and gout. No previous stroke symptoms
Normal physical and neurological exams6
Routine lab tests normal, as well as B12, folate, and TSH6
Structural MRI outcomes: small bilateral lacunar infarcts, small vessel ischemic changes, and age-appropriate atrophy6
An Amyvid PET scan is ordered due to the progressive nature of Paul’s cognitive decline and uncertain diagnosis3
Amyvid PET Scan Imaging Report3
NEGATIVE SCAN†
- Indicates sparse-to-no amyloid-beta neuritic plaques
- The negative scan is inconsistent with a neuropathological diagnosis of Alzheimer’s disease (AD) at the time of image acquisition, and makes it unlikely that Paul’s cognitive impairment is due to AD
The objective of Amyvid image interpretation is to provide an estimate of the brain amyloid-beta neuritic plaque density. Image interpretation is performed independently of a patient’s clinical features and relies upon the recognition of unique image features.
The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to inaccurate assessment.3
*Hypothetical patient.
†Amyvid PET scans are interpreted independently of the patient's clinical information.3
SELECT IMPORTANT SAFETY INFORMATION:
Risk for Image Misinterpretation and Other Errors
- Errors may occur in the estimation of brain amyloid beta neuritic plaque density during Amyvid image interpretation.
- The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to an inaccurate assessment. Extensive brain atrophy as well as motion artifacts that distort the image may limit the ability to distinguish gray and white matter on an Amyvid scan.
Perform image interpretation independently of the patient’s clinical information. For cases where there is uncertainty as to the location of cortical signal, use co-registered anatomical imaging to improve localization of signal.
PROCEDURE: BRAIN AMYLOID PET/CT SCAN
HISTORY: Cognitive impairment
COMPARISON: None
RADIOPHARMACEUTICAL: 10mCi Amyvid (florbetapir F 18)
TECHNIQUE: PET/CT imaging was performed 30-50 minutes following the intravenous administration of 10mCi Amyvid (florbetapir F 18). Images were obtained from the level of the vertex to the base of the skull. Axial, sagittal, and coronal PET reconstructions were acquired.
Corresponding CT images were reviewed in axial, coronal, and sagittal planes. CT scan was a limited noncontrast study and used for anatomical correlation and attenuation correction.
COMMENT: There is no increased tracer uptake seen in the cortical cerebral gray matter. The brain shows normal gray-white contrast throughout. The cerebellum has no evidence of abnormal uptake.
Tracer distribution is otherwise unremarkable.
CT (NONDIAGNOSTIC, PERTINENT FINDINGS ONLY): There is mild cerebral volume loss without midline shift or mass effect.
IMPRESSION: Negative scan, indicating sparse to no beta-amyloid neuritic plaques
NOTE: Amyvid is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline
- Selection of patients who are indicated for amyloid beta–directed therapy as described in the prescribing information of the therapeutic products
CT=computed tomography; MCI=mild cognitive impairment; MOCA=Montreal Cognitive Assessment; MRI=magnetic resonance imaging; PET=positron emission tomography; TSH=thyroid-stimulating hormone.
Learn about the importance of AD pathology
ACT EARLYReferences:
- Gauthier S, Rosa-Neto, P, Morais JA, et al. World Alzheimer Report 2021: Journey Through the Diagnosis of Dementia. London, England: Alzheimer’s Disease International; 2021. Accessed January 25, 2023. https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf
- DiBenedetti DB, Slota C, Wronski SL, et al. Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. 2020;12(1):90. doi: 10.1186/s13195-020-00659-6
- Amyvid (florbetapir F 18 injection). Prescribing Information. Lilly USA, LLC.
- Porsteinsson AP, Isaacson RS, Knox S, et al. Diagnosis of early Alzheimer's disease: clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386. doi:10.14283/jpad.2021.23
- Alzheimer's Association. 2025 Alzheimer's disease facts and figures. Alzheimers Dement. Published online April 29, 2025. doi:10.1002/alz.70235
- Atri A, Dickerson BC, Clevenger C, et al. Alzheimer’s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer’s Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for primary care. Alzheimers Dement. Published online December 23, 2024. doi:10.1002/alz.14333